Citadel Advisors
CSTL icon

Citadel Advisors’s Castle Biosciences CSTL Stock Holding History

Citadel Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$798K Sell
32,500
-8,100
-20% -$265K ﹤0.01% 8188
2025
Q4 		$1.58M Buy
40,600
+16,300
+67% +$525K ﹤0.01% 6398
2025
Q3 		$553K Buy
+24,300
New +$494K ﹤0.01% 8878
2025
Q2 		– Sell
-9,500
Closed -$190K – 12891
2025
Q1 		$190K Sell
9,500
-31,700
-77% -$785K ﹤0.01% 10524
2024
Q4 		$1.1M Sell
41,200
-14,800
-26% -$451K ﹤0.01% 6816
2024
Q3 		$1.6M Buy
56,000
+43,600
+352% +$1.11M ﹤0.01% 5928
2024
Q2 		$270K Sell
12,400
-23,900
-66% -$533K ﹤0.01% 9341
2024
Q1 		$804K Buy
36,300
+29,700
+450% +$646K ﹤0.01% 7382
2023
Q4 		$142K Sell
6,600
-43,100
-87% -$759K ﹤0.01% 10462
2023
Q3 		$839K Buy
49,700
+41,800
+529% +$731K ﹤0.01% 6947
2023
Q2 		$108K Sell
7,900
-4,900
-38% -$99.3K ﹤0.01% 10807
2023
Q1 		$291K Sell
12,800
-10,400
-45% -$254K ﹤0.01% 9442
2022
Q4 		$546K Sell
23,200
-5,900
-20% -$137K ﹤0.01% 8052
2022
Q3 		$759K Buy
+29,100
New +$816K ﹤0.01% 7585
2021
Q4 		– Sell
-17,600
Closed -$1.17M – 13898
2021
Q3 		$1.17M Buy
17,600
+2,300
+15% +$162K ﹤0.01% 7750
2021
Q2 		$1.12M Sell
15,300
-11,700
-43% -$773K ﹤0.01% 8066
2021
Q1 		$1.85M Buy
27,000
+12,100
+81% +$909K ﹤0.01% 6580
2020
Q4 		$1M Buy
+14,900
New +$808K ﹤0.01% 6791

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's CSTL Position: Q1 2026 in Review

Citadel Advisors reduced its Castle Biosciences (CSTL) stake by 67% in Q1 2026, selling an estimated $8.04M and leaving 120,977 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #5285.

Citadel Advisors first reported a position in CSTL in Q3 2019 and has held it in 26 quarters since. The position peaked at $22.2M in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Citadel Advisors held 120,977 shares of Castle Biosciences worth $2.97M as of Q1 2026.
  • Citadel Advisors sold 245,379 Castle Biosciences shares in Q1 2026, an estimated $8.04M.
  • Castle Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5285 holding.
  • Citadel Advisors first reported a position in Castle Biosciences in Q3 2019 and has held it in 26 quarters since.
  • Citadel Advisors's Castle Biosciences position peaked at $22.2M in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.